ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Sanofi buys rights to Principia’s BTK inhibitor
pharmatimes
November 13, 2017Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm. -
Study Confirms Link Between SGLT2 inhibitors and Diabetic Ketoacidosis
drugs.com
June 08, 2017A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns.
Pharma Sources Insight July 2025
